Sugi Predict

Sugi Predict / Compounds / SCHEMBL1600309

SCHEMBL1600309

SCHEMBL1600309

Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)O)cc1

nearest known ligand 0.82

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CDK8 P49336 2/20 0.82
▸ MAPK14 Q16539 9/20 0.78
▸ MAPK13 O15264 7/20 0.76
▸ MAPK12 P53778 6/20 0.76
▸ MAPK11 Q15759 6/20 0.76
▸ PTK2 Q05397 5/20 0.66
▸ CYP2D6 P10635 2/20 0.66
▸ CYP2C9 P11712 2/20 0.66
▸ DDR2 Q16832 2/20 0.65
▸ JAK2 O60674 1/20 0.64
▸ GAA P10253 1/20 0.62
▸ CYP2C8 P10632 1/20 0.62
▸ CCNC P24863 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9967321 0.91 CDK8 (0.78) CDK8MAPK14MAPK13MAPK12MAPK11
SCHEMBL1012719 0.91 MAPK13 (0.78) CDK8MAPK14MAPK13MAPK12MAPK11
SCHEMBL27217836 0.90 MAPK14 (0.72) CDK8MAPK14MAPK13MAPK12MAPK11
SCHEMBL3621438 0.90 CDK8 (0.67) CDK8MAPK14MAPK13MAPK12MAPK11
SCHEMBL19303194 0.90 CDK8 (1.00) CDK8MAPK14MAPK13MAPK12MAPK11
SCHEMBL18744685 0.90 CDK8 (0.76) CDK8MAPK14MAPK13MAPK12MAPK11
SCHEMBL15946922 0.90 CDK8 (0.76) CDK8MAPK14MAPK13MAPK12MAPK11
SCHEMBL13791346 0.89 MAPK14 (0.79) CDK8MAPK14MAPK13MAPK12MAPK11
SCHEMBL3939655 0.88 MAPK14 (0.75) CDK8MAPK14MAPK13MAPK12MAPK11
SCHEMBL3533400 0.88 MAPK14 (0.95) MAPK14MAPK13MAPK12MAPK11PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2819998-B1 CRYSTALLINE FORMS OF 1-(3-TERT-BUTYL-1-P-TOLYL-1H-PYRAZOL-5-YL)-3-(5-FLUORO-2-(1-(2-HYDROXYETHYL)-1H-INDAZOL-5-YLOXY)BENZYL)UREA HYDROCHLORIDE ARRAY BIOPHARMA INC (US) 2022-04-06 — — EP claimed
US-20240158394-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2024-05-16 — — US disclosed
WO-2024059200-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2024-03-21 — — WO disclosed
WO-2023237759-A1 DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR ANAGENESIS BIOTECHNOLOGIES (FR) 2023-12-14 — — WO disclosed
EP-4289427-A1 DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR. Anagenesis Biotechnologies (FR) 2023-12-13 — — EP disclosed
US-11634406-B2 Inhibitor of p38 MAP kinase RESPIVERT LTD. (GB) 2023-04-25 — — US disclosed
US-20230089368-A1 POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES ANAGENESIS BIOTECHNOLOGIES S.A.S. (FR) 2023-03-23 — — US disclosed
EP-4029501-A1 COMBINATION OF POLYAROMATIC UREA DERIVATIVES AND GLUCOCORTICOID OR HDAC INHIBITOR FOR THE TREATMENT OF DISEASES OR CONDITIONS ASSOCIATED WITH MUSCLE CELLS AND/OR SATELLITE CELLS Anagenesis Biotechnologies (FR) 2022-07-20 — — EP disclosed
EP-3999057-A1 POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES ANAGENESIS BIOTECHNOLOGIES SAS (FR) 2022-05-25 — — EP disclosed
US-11142515-B2 Pyrazolyl-ureas as kinase inhibitors RESPIVERT LIMITED (GB) 2021-10-12 — — US disclosed
US-20100093734-A1 CYTOKINE INHIBITORS ITHERX PHARMACEUTICALS, INC. (US) 2010-04-15 — — US disclosed
US-7652015-B2 Suppression cytokines , tumor necrosis factor ELI LILLY AND COMPANY (US) 2010-01-26 — — US disclosed
EP-1987022-A1 PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES Pfizer Products Inc. (US) 2008-11-05 — — EP disclosed
US-20080269244-A1 Kinase Inhibitors ELI LILLY AND COMPANY 2008-10-30 — — US disclosed
EP-1960394-A2 PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER Bayer HealthCare AG (DE) 2008-08-27 — — EP disclosed
EP-1943243-A1 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2008-07-16 — — EP disclosed
WO-2007091176-A1 PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES PFIZER PRODUCTS INC. (US) 2007-08-16 — — WO disclosed
WO-2007059202-A2 PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER BAYER HEALTHCARE AG (DE) 2007-05-24 — — WO disclosed
WO-2007053394-A1 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2007-05-10 — — WO disclosed
US-20050107399-A1 Cytokine inhibitors KEMIA, INC. 2005-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107399-A1 Cytokine inhibitors TNF, IL1RN, IL1A CDK8 2319/4885MAPK14 371/4885MAPK13 765/4885
US-20100093734-A1 CYTOKINE INHIBITORS TNF, IL1RN, IL1A CDK8 2319/4885MAPK14 371/4885MAPK13 765/4885
US-20230089368-A1 POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES CKMT1A; CKMT1B, TNNC1, UBQLN2 CDK8 287/4885MAPK14 2601/4885MAPK13 1703/4885
US-11142515-B2 Pyrazolyl-ureas as kinase inhibitors MAPK1, MAP3K1, MAP3K8 CDK8 248/4885MAPK14 12/4885MAPK13 33/4885
US-11634406-B2 Inhibitor of p38 MAP kinase MAPK1, MAPKAPK2, MAPK10 CDK8 477/4885MAPK14 9/4885MAPK13 16/4885
US-20240158394-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 CDK8 500/4885MAPK14 694/4885MAPK13 670/4885
US-20080269244-A1 Kinase Inhibitors MAP3K1, MAP3K20, MAP3K19 CDK8 338/4885MAPK14 58/4885MAPK13 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.